Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization
"Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical trial exclusively for high-risk group" SEOUL, South Korea, Aug. 28,...
“Application and Awareness of Thermal Paper in Hong Kong” – Laboratory Testing and Survey Findings
80% of receipts contain toxins, 70% exceed safety standards; Using receipts for expense claims, e-receipts are eco-friendly and cost-saving HONG KONG , Aug. 28, 2024 /PRNewswire/ -- In today's fast-paced and highly consumer-driven society, thermal paper has become an indispensable part of our daily lives, used for printing receipts, invoices and other transaction documents. However, the use of thermal paper...
Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical
SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered into an exclusive distribution agreement with Jiangsu NowYon Medical Limited ("NowYon Medical"). The agreement marks a significant...
Laifen to Launch World’s First Titanium Electric Toothbrush at IFA 2024
BERLIN, Aug. 28, 2024 /PRNewswire/ -- Laifen, a pioneering lifestyle-tech brand, is set to break new ground in oral care with the launch of the Laifen Wave Electric Toothbrush Titanium at IFA Berlin 2024. This marks Laifen's third appearance at IFA, reflecting its rapid growth and consistent commitment to the global market. Since its inception in 2019, Laifen has...
Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist
SEOUL, South Korea, Aug. 28, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an orally available small molecule GLP-1 agonist being developed for obesity and...
Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%
RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - recombinant human albumin® 20% (rHA), becoming the first Indian company to achieve this milestone. The positive results underscore...
Jenscare, with innovative TTVR, releases 2024H1 interim results
BEIJING, Aug. 28, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 ended June 30, 2024. Financial Highlights Net Loss attributable to common shareholders was RMB 102 million (US$ 14 million), narrowed...
Everest Medicines Announces Interim Results for First Half of 2024
SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2024 along with a corporate update. "Our total revenue for the first half of 2024 reached RMB 301.5 million, a...
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®, 18F-floretyrosine or 18F-FET), an investigational PET agent for the characterisation of progressive or recurrent glioma (brain...
Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market
Singapore-based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL® Success provides "template for the internationalization of future vaccine and biologics development from Singapore" – Dr. Raman Rao, CEO, Hilleman Laboratories Hilleman Laboratories Singapore hub advancing global health equity by developing portfolio of vaccines that could benefit up to 500 million people in low- and...
